‘Cerebroactive’ Drugs

@article{Spagnoli2012CerebroactiveD,
  title={‘Cerebroactive’ Drugs},
  author={Alberto Spagnoli and Gianni Tognoni},
  journal={Drugs},
  year={2012},
  volume={26},
  pages={44-69}
}
SummaryWhile their importance in the market-place is steadily increasing in developed (mainly continental Europe) and even in developing countries, compounds included in the broad category of ‘cerebroactive’ drugs hardly rate a mention in reference pharmacology and therapeutics textbooks. It is an undeniable fact, however, that the principal users or targets of this drug class, mainly elderly people, represent an increasingly worrying problem, with their often puzzling cohort of ill-definable… 
2 Citations

Effects of Piracetam as an Adjuvant Therapy on Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

TLDR
Piracetam as a short-term adjuvant treatment to methylphenidate can have considerable therapeutic effect and safety profile in children with ADHD and deserves further exploration to assess its potentialities in ADHD treatment.

Getting More Than You Paid For: Unauthorized "Natural" Substances in Herbal Food Supplements on EU Market.

As the population in the industrialized world develops preference for what is perceived as a natural and holistic way of disease treatment, the popularity and the number of food supplements on the

References

SHOWING 1-10 OF 163 REFERENCES

“Senile Dementia”: A Changing Perspective

  • D. Alexander
  • Medicine, Psychology
    British Journal of Psychiatry
  • 1972
TLDR
It is shown that the spirit of enquiry and the descriptive contributions of the early writers seem to have been tempered more by the degree of optimism or pessimism with which they anticipated the intellectual and behavioural foibles of old age, than by a desire to explore and evaluate systematically its possible deviations.

Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo.

TLDR
Comparisons of the two groups of subjects disclosed that the Hydergine-treated group showed statistically significantly more improvement in most of the variables measured, especially during the last three months of treatment.

Orally Administered Betahistine and Regional Cerebral Blood Flow in Cerebrovascular Disease

TLDR
’5 These views were based largely on observations in animals of the “intracerebral steal” phenomenon produced by tile administration of high concentrations of 002 as an inhalation mixture in severe and acute experimental cerebral infarction, and poorly defined and uncontrolled studies of the effects of vasodilating agents on the clinical course of acute and chronic stroke patients.

The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline ('Trental' 400).

  • D. Harwart
  • Medicine, Psychology
    Current medical research and opinion
  • 1979
TLDR
Improvements in clinical symptoms were recorded significantly more frequently with pentoxifylline, and the reductions in severity were also significantly more marked with the test conipound than with placebo.

Rheoencephalographic and Other Studies of Betahistine in Humans. IV. Prolonged Administration with Improvement in Arteriosclerotic Dementia

TLDR
Bethahistine acts in humans as a potent and efficacious cerebral and peripheral microcirculatory and arterial vasodilator which can significantly improve cerebrovascular insufficiency and any associated dementia, no matter how severe either may be and despite the possible presence of large-vessel disease.

Clinical evaluation of (-)eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia.

The activity of (-)eburnamonine, a substance acting on the cerebral circulation and metabolism, was compared with that of nicergoline in a double-blind study carried out on a group of 28 patients (16

Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns

TLDR
It is demonstrated by psychometric testing that Hydergine compensated the signs of dementia, present in the placebo group, and in some patients actually brought about a significant improvement in mental activity.

An Ergot Alkaloid Preparation (Hydergine) in the Treatment of Dementia: Critical Review of the Clinical Literature

TLDR
Qualitative and quantitative comparisons of improvement in symptoms showed that Hydergine consistently produced statistically significant improvement in 13 symptoms associated with dementia, but because of the small magnitude of the improvement and the absence of indications of long‐term benefit, it would seem to be of minor value in dementia therapy.

Epidemiological Impact of Psychotropic Drugs. Edited by G. Tognoni, C. Bellantuono and M. Lader. (Pp. 393; £32.85.) Elsevier/North-Holland: Amsterdam. 1981.

  • J. Murray
  • Psychology
    Psychological Medicine
  • 1982
Elaine Showalter's article on women and insanity also unearths some interesting facts. Whereas in the early nineteenth century men far outnumbered women as asylum inmates, with the asylum population
...